Best response of target lesions to axitinib for patients within each sarcoma stratum.
deaths, sarcoma
DISEASE PROGRESSION, DISEASE, SARCOMA
At baseline the size of each target lesion (diameter in mm) at any timepoint was measured and then at each disease evaluation visit the size of each target lesion was re-measured, with the percentage change calculated. For patients whose total sum of diameters decreased the waterfall plots present the largest reported decrease in size alongside the associated overall response. For patients whose total sum of diameters increased the waterfall plot presents the smallest increase alongside the associated overall response. Panel A A The median PFS of all sarcoma patients was 2.9 months (95%CI: 2.6, 3.8) consisting of 122 disease progressions and 13 deaths (Fig. 